Squarepoint Ops LLC Galectin Therapeutics Inc Transaction History

Squarepoint Ops LLC

  • $62.8 Billion
  • Q3 2024

A detailed history of Squarepoint Ops LLC transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Squarepoint Ops LLC holds 27,435 shares of GALT stock, worth $72,977. This represents 0.0% of its overall portfolio holdings.

Number of Shares
27,435
Previous 84,074 67.37%
Holding current value
$72,977
Previous $190,000 60.53%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$2.04 - $2.86 $115,543 - $161,987
-56,639 Reduced 67.37%
27,435 $75,000
Q2 2024

Aug 14, 2024
BUY
$2.13 - $4.2 $76,976 - $151,783
36,139 Added 75.39%
84,074 $190,000
Q1 2024

May 15, 2024
BUY
$1.6 - $2.44 $76,696 - $116,961
47,935 New
47,935 $114,000
Q1 2022

May 16, 2022
SELL
$1.61 - $2.31 $21,223 - $30,450
-13,182 Closed
0 $0
Q4 2021

Feb 14, 2022
SELL
$2.07 - $3.8 $53,838 - $98,834
-26,009 Reduced 66.36%
13,182 $27,000
Q3 2021

Nov 15, 2021
SELL
$2.59 - $4.15 $43,866 - $70,288
-16,937 Reduced 30.18%
39,191 $152,000
Q2 2021

Aug 16, 2021
BUY
$2.07 - $5.1 $116,184 - $286,252
56,128 New
56,128 $180,000
Q1 2020

May 15, 2020
SELL
$1.51 - $3.0 $21,950 - $43,611
-14,537 Closed
0 $0
Q4 2019

Feb 14, 2020
BUY
$2.79 - $4.32 $1,774 - $2,747
636 Added 4.58%
14,537 $42,000
Q3 2019

Nov 14, 2019
BUY
$3.0 - $4.05 $11,364 - $15,341
3,788 Added 37.46%
13,901 $51,000
Q2 2019

Aug 14, 2019
BUY
$3.61 - $5.0 $36,507 - $50,565
10,113 New
10,113 $42,000
Q4 2018

Feb 14, 2019
SELL
$3.43 - $5.74 $101,270 - $169,473
-29,525 Closed
0 $0
Q3 2018

Nov 14, 2018
BUY
$3.68 - $6.93 $47,644 - $89,722
12,947 Added 78.1%
29,525 $177,000
Q2 2018

Aug 14, 2018
BUY
$3.16 - $9.16 $52,386 - $151,854
16,578 New
16,578 $105,000

Others Institutions Holding GALT

# of Institutions
90
Shares Held
9.44M
Call Options Held
1.16M
Put Options Held
1.98M
View Full List

About GALECTIN THERAPEUTICS INC

GALT Quotes by TradingView
  • Ticker GALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,426,000
  • Market Cap $158M
  • Description
  • Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...
More about GALT
Track This Portfolio

Track Squarepoint Ops LLC Portfolio

Follow Squarepoint Ops LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email